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Though HCV infection is a serious public health problem, some aspects of its biology are still not well understood,
such as its transmission through seminal fluid and sexual transmission. We looked for HCV in the semen of
infected patients. Thirteen patients were included. Semen fractions (seminal plasma, leukocytes and spermatozoa)
were separated with 45% and 90% Percoll gradients. The HCV-RNA in blood and semen fractions was extracted
using the same protocol (AMPLICOR Roche) and was detected using the qualitative Roche Amplicor test and by
agarose gel electrophoresis, with ethidium bromide staining. The mean age of the patients was 40.7 years. Risk
factors for the acquisition of HCV included injectable and inhaled drug use in six (42.8%), blood transfusion in four
(28.6%), and no risk factors in four (28.6%) patients. Genotype 1 was detected in 62% of the patients, followed by
genotype 3 in 23% and genotype 2 in 15%. All blood samples were positive, regardless of the technique used for
detection. All semen samples identified by Roche Amplicor and analyzed by agarose gel electrophoresis were
negative. Among the 52 semen samples (total and fractions) identified by the Roche Amplicor method, 45 (87%) were
inhibited. A negative result was recorded for one (1.9%) total semen sample, one (1.9%) leukocyte and four (7.7%)
seminal plasma fractions. Only one (1.9%) sample of the spermatozoon fraction was positive. The results obtained
suggested false-negative reactions for the semen samples.
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Various studies suggest that the risk of sexual transmission
of hepatitis C virus (HCV) is minimal or even inexistent, with
its incidence ranging from 0 to 3% [1,2]. The first report
discussing the sexual transmission of HCV, in which multiple
sex partners were considered to be a risk factor, was published
by Alter et al. in 1989 [3].
As is the case for sexual transmission, the risk of HCV
transmission through seminal fluid is also controversial. Risk
factors that may increase the probability of transmission are
the type of relationship, since monogamic couples tend to
present lower transmission rates than individuals reporting
sex with multiple partners, sexual relations that involve trauma,
co-infection with acquired immunodeficiency virus (HIV),
partners using drugs, associated sexually-transmitted
diseases, paid sex, and a long-term relationship (>10 years)
with an HCV-positive partner [4-6].
The direction of sexual transmission of HCV from men to
women has been reported by Rooney and Gilson [7], who
showed that the estimated risk of HCV infection is 3.7 times
higher in women with HCV-positive partners. Cavalheiro et al.
[8] studied a series of 24 couples with a diagnosis of hepatitis
C; there was an average viral similarity of 98.3% for 22/24 (91.7%)
couples. In that study, the NS5b-HCV region was chosen for
phylogenetic analysis. Nine couples attracted attention because
the women did not report any risk factor for acquisition of the
virus, whereas all nine men reported one or more risk factors. In
this case, the average genomic similarity was 98%. That study
supports the hypothesis of infection from men to women.
Studies analyzing semen by molecular biology techniques
have reported difficulty in eliminating natural inhibitors present
in the sample, which frequently leads to false-negative results
[9]. Cassuto et al. [10], in a study of semen from 35 men, reported
difficulty in removing inhibitors during HCV-PCR, with only
five men testing positive, suggesting false-negative results.
Various investigators have been able to detect HCV in semen,
while others could not. The difficulty in isolating this virus
from body fluids, especially semen, is probably due to the
presence of inhibitors and the lack of standardized techniques
and protocols for RNA extraction and reverse transcription
and polymerase amplification (RT-PCR); these factors may
contribute to false-negative results [9,11].
Our objective was to investigate whether HCV is present
in semen samples from infected patients.
Material and Methods
Patient Selection
Between June and December 2004, male patients with a
clinical and laboratory diagnosis of HCV infection were
recruited from the Hepatitis Outpatient Clinic of the Infectious
Diseases Department. All recruited patients signed an informed
consent agreement.
Blood and Semen Collection and Preparation
Blood was collected from patients into 10mL dry vacuum
tubes, after an 8 to 12-h fast. Semen samples were obtained by
self-masturbation, after a period of sexual abstinence of at
least three days. Blood and semen samples were stored at -
80°C until the time of use.
In addition to an aliquot of total semen, fractions were
isolated on 90 and 45% Percoll gradients. The samples were
centrifuged for 30 min. at 3,000 rpm, and the following three
phases were obtained: seminal plasma, leukocytes and
spermatozoa.
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Serum
All serum samples were analyzed with the qualitative
Amplicor HCV test, version 2.0 (Roche Diagnostics Corp.,
Indianapolis, IN, USA). If positive, the blood samples were
genotyped with INNO-LiPA HCV II kit (INNO-LIPA HCV,
Versant Bayer, Tarrytown, NY, USA).
Semen
All semen samples were analyzed with the qualitative
Amplicor HCV test, version 2.0 (Roche Diagnostics Corp.,
Indianapolis, IN, USA). After the end of the PCR-HCV reaction,
the presence of HCV in semen samples was revealed by two
methods: i) electrophoresis in agarose gel and ii) Roche
Amplicor test by colorimetric determination.
Electrophoresis Agarose Gel Detection
The PCR-HCV products were detected by 2% Agarose
Gel electrophoresis, stained with ethidium bromide and
observed under ultraviolet light [13-15].
Amplicor HCV Test, v 2.0
The Amplicor HCV Test, v 2.0, is an RT-PCR in a manual,
microwell format that amplifies a 244-nucleotide segment of
the 5’-UTR of the HCV genome. The test was performed at all
sites according to manufacturer’s instructions, as previously
described. HCV RNA optical density (OD) values were
interpreted as follows: <0.3, negative; ≥0.3 and <1.0, equivocal;
and ≥1.0, positive. An OD value of 0.3 was used as the cutoff
for the internal control RNA. Any specimen with an OD value
<0.3 for both HCV and internal control wells was considered
to be inhibited [12].
HCV Genotyping by the Line Probe Assay (LiPA)
RNA was isolated from serum and 5'-UTR genotyping was
performed with the INNO-LiPA HCV II kit (INNO-LIPA HCV,
Versant Bayer, Tarrytown, NY, USA), according to
manufacturer’s instructions. Briefly, the 5'-UTR region was
amplified with biotinylated primers. The biotin-labeled PCR
products were then reverse hybridized to specific probes
attached to nitrocellulose strips, and the results were developed
as a purple precipitate that formed a positive line on the strip.
The HCV type was deduced on the basis of the patterns of
hybridizing bands using the LiPA interpretation chart [16].
Results
The mean age of the 13 patients was 40.8 years (range: 28-
50, median: 45 years). The mean time since the diagnosis of
HCV infection was 7.15 years (range: 2-14, median: 7 years).
Serum
Analysis was made of the same HCV-PCR product by
the Roche Amplicor method and agarose gel electrophoresis
with ethidium bromide staining; all serum samples tested
positive by these two techniques, i.e., all patients presented
viremia.
Semen
The products analyzed with the Amplicor HCV test and
revealed by agarose electrophoresis gel detection were
negative for all samples of total semen and fractions
(spermatozoa, leukocytes and seminal plasma).
The same semen and seminal fractions (52 samples)
analyzed by optical density (Roche Amplicor method) revealed
45 (86.5%) of the results to be inhibited. Negative results were
detected for one (1.9%) total semen sample, one (1.9%)
leukocyte and 4 (7.7%) seminal plasma fraction. Only one
(1.9%) sample of the spermatozoon fraction was positive.
Discussion
The inhibition of HCV-PCR in semen samples was clearly
and unquestionably demonstrated, with 45 (87%) of the 52
reactions involving total semen and fractions, spermatozoa,
leukocytes and seminal plasma presenting inhibited results
(Table 3). Amplicor HCV qualitative tests have an internal
control, permitting the evaluation of the efficiency of the tests.
In contrast, when the products of PCR (Amplicor HCV
qualitative tests, v. 2.0 (Roche Diagnostics) were examined on
the agarose gel with ethidium bromide staining, all samples
tested negative. False-negative results were obtained with
the in-house nested HCV-PCR method used in this preliminary
study (data not shown). The presence of HCV-PCR inhibitors
in semen masks the results and impairs their interpretation, a
fact explaining the wide disparity in HCV detection rates
reported in the international literature, which vary from 0 to
36% [10,11,17-25].
Our results support the hypothesis of the presence of
HCV in semen samples from infected patients and also indicate
the need for more sensitive tests and/or laboratory measures
that remove HCV-PCR inhibitors so that reliable results can
be obtained. Analysis of the HCV-PCR products by
electrophoresis of an agarose gel and ethidium bromide
staining apparently yielded false-negative results for all the
semen samples. The commercial Roche Amplicor test
demonstrated interference from inhibitors present in the semen
samples, because it uses an internal control that guarantees
the efficacy of the reaction; but it was unable to eliminate the
inhibitors.
According to Abou-Setta [26] the contradictory results of
HCV-PCR in semen can be explained by i) the different
techniques used, ii) different HCV-PCR sensitivities, and iii)
presence of inhibitors in semen that lead to false-negative
results. Furthermore, this author reported that viral
concentrations in semen samples go through rapid variations
and indicated that inhibition might be due to the action of
RNases or lipoperoxidase. The enzyme Taq polymerase may
be inhibited by seminal fluid enzymes, lactoferrin, peroxidase
or zinc residues [26].
The two main adaptations needed for testing semen are
elimination of PCR inhibitors, especially frequent in seminal
plasma, and the use of small sample volumes. The choice of
the extraction protocol is critical [9].
HCV in Semen
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Information regarding the quantity of circulating virus is
important; it helps increase the probability of HCV detection in
semen and demonstrates the potential of sexual transmission.
Nyamaty et al. [27] showed that the quantity of virus in blood is
correlated with the virus in semen. The distribution of HCV viral
types was compatible with the prevalence that was previously
reported for Brazil, with most of the (infected) population being
infected with HCV genotype 1, followed by genotypes 3 and 2
(Table 2) [28]. On average, 40 to 50% of patients infected with
HCV indicate no specific source of acquisition of the virus [26].
We had 28.6% unknown risk factors (Table 1).
This preliminary study of semen samples by HCV-PCR
indicates the need for new research protocols in order to obtain
more reliable results. Other laboratory resources or even new
techniques for viral detection should be tested for the
evaluation of semen samples so that the results better
correspond to reality.
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Table 1. Distribution of the patients according to risk factors
for the acquisition of HCV.
Epidemiology No. of %
patients
Use of injectable and/or inhaled drugs 6 42.8%
Blood transfusion 4 28.6%
Unknown 4 28.6%
Table 2. Distribution of the patients according to HCV
subtype.
Genotype No. of patients (%)
1a  5 (38.5%)
1b  1 (7.7%)
1a/1b  2 (15.4%)
2b  2 (15.4%)
3a  3 (23.0%)
Total 13 (100%)
Table 3. Results of HCV-PCR with the Roche Amplicor test.
Patient Serum Total semen Spermatozoa Leukocytes Seminal plasma
1 Positive Inhibition Inhibition Inhibition Inhibition
2 Positive Inhibition Inhibition Inhibition Inhibition
3 Positive Inhibition Inhibition Inhibition Negative
4 Positive Negative Positive Negative Negative
5 Positive Inhibition Inhibition Inhibition Inhibition
6 Positive Inhibition Inhibition Inhibition Inhibition
7 Positive Inhibition Inhibition Inhibition Inhibition
8 Positive Inhibition Inhibition Inhibition Inhibition
9 Positive Inhibition Inhibition Inhibition Negative
10 Positive Inhibition Inhibition Inhibition Inhibition
11 Positive Inhibition Inhibition Inhibition Negative
12 Positive Inhibition Inhibition Inhibition Inhibition
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